Lenvatinib mesylate

Lenvatinib mesylate
Product Description

Lenvatinib mesylate (CAS No.: 857890-39-2)Indications: For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid carcinoma (DTC).

KINHOO PHARMACEUTICAL CO.,LTD

  • CN
  • 2017
    On CPHI since
  • 500 - 999
    Employees
Company types
Pharmaceutical company
Specifications
  • CAS Registry Number
    857890-39-2
  • Supplied from
    China

KINHOO PHARMACEUTICAL CO.,LTD

  • CN
  • 2017
    On CPHI since
  • 500 - 999
    Employees
Company types
Pharmaceutical company

More Products from KINHOO PHARMACEUTICAL CO.,LTD (4)

  • Sorafenib tosylate

    Product Sorafenib tosylate

    Sorafenib tosylate (CAS No.: 475207-59-1) Indications: For the treatment of patients with advanced renal cell carcinoma (RCC). For the treatment of patients with unresectable hepatocellular carcinoma (HCC). For the treatment of patients with locally recurrent or metastatic, progressive, differentia...
  • Vardenafil hydrochloride

    Product Vardenafil hydrochloride

    Vardenafil hydrochloride (CAS No.: 330808-88-3)Indications: For the treatment of erectile dysfunction.

  • Ibuprofen arginine

    Product Ibuprofen arginine

    Ibuprofen arginine (CAS No.: 57469-82-6)Indications: For relief of toothache, dysmenorrhea, pain caused by injury (e.g., athletic injuries), joint and ligament pain, back pain, headache, and fever caused by influenza.

  • Ferrous succinate

    Product Ferrous succinate

    Indications: For the prevention and treatment of Iron Deficiency Anemia (IDA).